Compare CING & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CING | GECC |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.3M | 79.9M |
| IPO Year | N/A | N/A |
| Metric | CING | GECC |
|---|---|---|
| Price | $4.49 | $5.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $34.50 | $10.75 |
| AVG Volume (30 Days) | ★ 419.3K | 78.6K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 22.06% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.92 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $4.63 |
| 52 Week High | $11.89 | $11.45 |
| Indicator | CING | GECC |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 53.75 |
| Support Level | $3.50 | $5.40 |
| Resistance Level | $6.67 | $7.16 |
| Average True Range (ATR) | 0.39 | 0.27 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 13.76 | 45.56 |
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.